News >

Expert Unveils Untapped Potential in Radiotherapy for NSCLC

Caroline Seymour
Published: Tuesday, Apr 17, 2018

Ashley A.
Weiner, MD, PhD

Ashley A. Weiner, MD, PhD
Although the standard of care for patients with stage III unresectable non–small cell lung cancer (NSCLC) has been concurrent chemoradiotherapy at 60 Gy at 2 Gy/fraction, the addition of immunotherapy for those who have not progressed on chemoradiotherapy can offer an increased benefit, explains Ashley A. Weiner, MD, PhD.

State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, Weiner, assistant professor, Department of Radiation Oncology, University of North Carolina (UNC) at Chapel Hill School of Medicine, UNC Lineberger Comprehensive Cancer Center, discussed the expansions and limitations of radiotherapy in patients with NSCLC and ongoing efforts to enhance administration and efficacy.

OncLive®: Can you speak to the use of radiotherapy in patients with NSCLC?

Weiner: We are currently treating locally advanced or stage III lung cancer at 2 Gy/fraction at 60 Gy, and we’ve been doing that for a while. It’s safe and effective, but we’re looking to see if there is a more convenient and more efficacious approach for patients. We’re looking at ways to safely increase doses; some of these have been limited thus far with negative studies. Nonetheless, we’re investigating ways to administer higher doses per fraction, or use hypofractionation.

Can stereotactic body radiation boosts enable dose escalation?

It’s possible. There is a study run out of a single institution but opened at several institutions looking at that. It’s not something I would do off of a protocol. In that study, they found what they would claim to be the maximum-tolerated dose (MTD), but it hasn’t found its way into the standard of care yet.

How have the competing theories of radiation administration evolved?

A lot of people are still proponents of MTD. There is no evidence that exceeding 60 Gy at 2 Gy/fraction and potential fractionation is beneficial. You could perhaps go to 66 Gy, but in terms of reaching a higher MTD, you have to look at different strategies with some sort of boost or hypofractionation.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x